Welcome to our dedicated page for Cyclacel Phar Pr news (Ticker: CYCCP), a resource for investors and traders seeking the latest updates and insights on Cyclacel Phar Pr stock.
The CYCCP news page on Stock Titan tracks disclosures and press releases related to Cyclacel Pharmaceuticals, Inc.’s 6% Convertible Exchangeable Preferred Stock and the broader corporate developments of the issuer. Company communications describe Cyclacel as a clinical-stage biopharmaceutical company developing cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, with a key focus on the PLK1 inhibitor plogosertib in solid tumors and hematological malignancies.
News items for CYCCP include quarterly financial results, where Cyclacel reports cash resources, research and development spending, and general and administrative expenses, together with commentary on cost reductions, changes in research focus and going concern considerations. These updates often describe the impact of the liquidation of the UK subsidiary Cyclacel Limited, the deconsolidation of that entity’s results, and the company’s decision to concentrate resources on the plogosertib program.
Investors will also find scientific and clinical updates, such as press releases highlighting independent preclinical publications on plogosertib in biliary tract cancer and fibrolamellar hepatocellular carcinoma. These items summarize how PLK1 inhibition and potential biomarkers like BUBR1 or DNAJ–PKAc fusion status may relate to sensitivity to plogosertib, and they provide context for the company’s translational biology strategy.
Another category of CYCCP-linked news covers corporate and capital markets actions, including private placements of Series F Convertible Preferred Stock and associated warrants, amendments to preferred stock and warrant terms, reverse stock splits, and Nasdaq compliance updates. Press releases also detail the Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd., a Malaysian fire safety and protective equipment business, and describe shareholder approvals for share issuances and a corporate name change to Bio Green Med Solution, Inc.
By reviewing this news feed, holders and prospective investors in CYCCP can follow how Cyclacel’s oncology development activities, strategic transactions, financing steps and corporate rebranding are described in its own public statements and SEC-related communications.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has entered into an Exchange Agreement with FITTERS Diversified Berhad to acquire its subsidiary, Fitters Sdn. Bhd., through a share exchange transaction. Under the agreement, Cyclacel will issue common stock representing 19.99% of its outstanding shares to FITTERS, while existing Cyclacel stockholders will retain approximately 80.01% ownership of the combined company.
Post-transaction, Cyclacel will be renamed to Bio Green Med Solution, Inc. and will continue trading on Nasdaq under a new ticker symbol. The deal must close by August 31, 2025, and requires approval from both companies' stockholders. The transaction has already received unanimous approval from the Boards of Directors of all involved entities. No officers or directors from FITTERS or Fitters Sub will be appointed to Cyclacel.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced its Q4 2024 financial results and strategic updates. The company is streamlining operations to focus on developing plogosertib, a PLK 1 inhibitor for advanced cancers, following its acquisition from Cyclacel on March 10, 2025.
Financial highlights include:
- Pro forma cash and equivalents of $7.2M as of Dec 31, 2024
- R&D expenses decreased to $6.7M in 2024 from $19.2M in 2023
- Net loss reduced to $11.2M in 2024 from $22.6M in 2023
- Current cash expected to fund operations into Q2 2025
The liquidation of Cyclacel is expected to increase stockholders' equity by approximately $5.0M and significantly reduce R&D expenses in 2025. The company is developing a new oral formulation of plogosertib with improved bioavailability.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has secured $1.0 million through a private placement of convertible Series E Preferred Stock to accredited investors, completed on March 21, 2025. Each preferred share is convertible into 110 common shares, subject to stockholder approval per Nasdaq rules.
The company plans to use the net proceeds for working capital and general corporate purposes. Combined with existing cash reserves, this financing is expected to extend Cyclacel's cash runway into the third quarter of 2025. Preferred stockholders will be entitled to participate in any dividends declared on common stock on an as-converted basis.
The securities were issued under Regulation S of the Securities Act and were offered directly to investors without intermediaries. Arc Group and Rimon P.C. served as financial advisor and legal counsel, respectively.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) announced a significant change in control and leadership on February 26, 2025. Datuk Dr. Doris Wong Sing Ee acquired controlling interest through the purchase of convertible preferred stock from former interim CEO David Lazar for $6.3 million.
The transaction involved 1,000,000 shares of Series C and 1,745,262 shares of Series D Convertible Preferred Stock, which were converted into 2,650,000 and 191,978,820 common shares respectively. This resulted in the purchaser owning 70% of Cyclacel's outstanding shares.
Following the transaction, significant leadership changes occurred: David Lazar resigned as interim CEO, Datuk Dr. Doris Wong Sing Ee became CEO and Executive Director, and Kiu Cu Seng was appointed as Executive Director, Secretary and CFO. Additionally, multiple board members resigned or provided notice of resignation, with Chong Kwang Fock joining as an Independent Director.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has entered into a securities purchase agreement with investor David Lazar, who will invest $3.1 million through the purchase of convertible preferred stock. The deal includes 1,000,000 shares of Series C Preferred Stock at $1.00 per share (convertible to 2.65 common shares each) and 2,100,000 shares of Series D Preferred Stock (convertible to 110 common shares each).
As part of the agreement, significant board changes were announced, with David Lazar appointed as interim CEO, replacing Spiro Rombotis. The company also entered into a Warrant Exchange Agreement to exchange warrants for 24,844,725 common shares plus $1.1 million in cash.
The company must obtain stockholder approval for both the preferred stock conversion and warrant exchange. Cyclacel faces a February 6, 2025 deadline to comply with Nasdaq's minimum stockholders' equity requirement to avoid potential delisting. Management has been directed to reduce operating costs while exploring strategic alternatives.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) announced it is exploring strategic alternatives to preserve cash, including a potential transaction with investor David Lazar of Activist Investing, , subject to existing securityholder consent. The company's Board is reviewing strategies to realize value from assets and has directed management to reduce operating costs.
The company currently does not meet Nasdaq's continued listing requirements and faces potential delisting if compliance is not regained. Without securing a strategic transaction or additional funding, Cyclacel may be forced to cease operations, potentially resulting in stockholders losing part or all of their investment.
Cyclacel Pharmaceuticals announced the closing of a warrant exercise transaction, raising $2.1 million in gross proceeds. The company facilitated the exercise of existing warrants for 4,968,945 shares at a reduced price of $0.415 per share, down from the original $1.36. In exchange, Cyclacel issued new unregistered Series C and D warrants, each for 9,937,890 shares at $0.415 per share. The Series C warrants have a 5.5-year term, while Series D warrants expire in 18 months, both pending stockholder approval. The proceeds will be used for working capital and general corporate purposes.
Cyclacel Pharmaceuticals has entered into an agreement for the exercise of existing warrants to purchase 4,968,945 shares of common stock at a reduced price of $0.415 per share, down from the original $1.36. The company will issue new unregistered Series C and D warrants, each allowing purchase of up to 9,937,890 shares at $0.415 per share. The transaction is expected to generate $2.1 million in gross proceeds, which will be used for working capital and general corporate purposes. H.C. Wainwright & Co. serves as the exclusive placement agent.
Cyclacel Pharmaceuticals reported Q3 2024 financial results, highlighting initial safety and efficacy data from twelve patients in Phase 2 study of fadraciclib. Cash equivalents were $3.0 million as of September 30, 2024, down from $3.4 million at end-2023. Net loss decreased to $2.0 million from $6.0 million year-over-year. R&D expenses reduced to $1.0 million from $5.2 million in Q3 2023. The company faces potential Nasdaq delisting unless it meets minimum stockholders' equity requirement by December 24, 2024. Current cash is expected to fund operations into Q4 2024, with substantial doubt about continuing as a going concern.
Cyclacel Pharmaceuticals presented interim Phase 2 data for fadraciclib (fadra) monotherapy in advanced solid tumor patients with CDKN2A/B abnormalities at the 2024 EORTC-NCI-AACR Symposium. The study enrolled 12 patients in Cohort 8, with various cancer types including pancreatic, melanoma, and others. Out of six evaluable patients, two achieved stable disease: a melanoma patient (125 days treatment) and a squamous cell CUP patient with 11% tumor shrinkage (85+ days, ongoing). The drug showed good tolerability with no Grade 3 or higher adverse events. Two additional patients are ongoing but await first scans.
FAQ
What is the current stock price of Cyclacel Phar Pr (CYCCP)?
What is the market cap of Cyclacel Phar Pr (CYCCP)?
